Management

Return to Management
Ajay Madan, Ph.D., D.A.B.T. Vice President, Development linkedin

Dr. Madan is vice president of development for Crinetics. Prior to Crinetics, he was vice president of preclinical development at Neurocrine Biosciences. At Neurocrine, he was responsible for bioanalytical analysis, drug metabolism, pharmacokinetics, toxicology, and clinical pharmacology in support of a number of drug discovery and development programs. He also initiated and led the vesicular monoamine transporter 2 (VMAT2) inhibitor program for the treatment of tardive dyskinesia, resulting in the discovery of a best-in-class compound, valbenazine. Valbenazine has demonstrated efficacy and safety in Phase 2 and 3 clinical trials and was awarded fast-track status and breakthrough therapy designation by the FDA. Prior to Neurocrine, he was the chief scientific officer at XenoTech L.L.C., a research company that led the innovation of the current in vitro drug interaction platforms routinely used by all drug discovery and development companies. Dr. Madan is an author of more than 50 scientific publications, and he has been a diplomate of the American Board of Toxicology since 2005. He holds a B.Pharm. degree from Birla Institute of Technology and a Ph.D. in pharmacology and toxicology from the University of Kansas.

Relevant Publications

  • A pharmacokinetic evaluation of five H1 antagonists after an oral and intravenous microdose to human subjects.

    Madan A, O’Brien Z, Wen J, O’Brien C, Farber RH, Beaton G, Crowe P, Oosterhuis B, Garner RC, Lappin G, Bozigian HP. British Journal of Clinical Pharmacology. 2009; 67:288-98.

  • In vitro metabolism of indiplon and an assessment of its drug interaction potential.

    Madan A, Fisher A, Jin L, Chapman D, Bozigian HP. Xenobiotica. 2007; 37:736-52.

  • Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes.

    Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, Downey AD, Czerwinski M, Forster J, Ribadeneira MD, Gan LS, LeCluyse EL, Zech K, Robertson P Jr., Koch P, Antonian L, Wagner G, Yu L, Parkinson A. Drug Metabolism and Disposition. 2003; 31:421-31.

  • In vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs.

    Madan A, Usuki E, Burton LA, Ogilvie BW, Parkinson A. In: Rodriguez AD. Drug-Drug Interactions. Drugs and the Pharmaceutical Sciences. Vol. 116, p.217-94, Marcel and Dekker, New York; 2002.

Return to Management